Home Stock

Stock Research: Mochida Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Mochida Pharmaceutical

TYO:4534 JP3922800002
88
  • Value
    45
  • Growth
    69
  • Safety
    Safety
    96
  • Combined
    82
  • Sentiment
    59
  • 360° View
    360° View
    88
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Mochida Pharmaceutical Co Ltd is a Japan-based company primarily engaged in the production and sale of drugs. It operates in the Pharmaceutical-related segment, focusing on pharmaceutical products, and the Healthcare segment, dealing with quasi drugs and cosmetic products. The company also handles real estate brokerage and management, building maintenance, personal affairs agency, accounting, and purchasing businesses. It primarily operates in Japan. In the last fiscal year, the company had 1508 employees, a market cap of $720 million, profits of $359 million, and revenue of $701 million.

more

ANALYSIS: With an Obermatt 360° View of 88 (better than 88% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Mochida Pharmaceutical are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Mochida Pharmaceutical. The consolidated Growth Rank has a good rank of 69, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 69% of competitors in the same industry. The consolidated Safety Rank at 96 means that the company has a financing structure that is safer than 96% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 59, which means that professional investors are more optimistic about the stock than for 59% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 45, meaning that the share price of Mochida Pharmaceutical is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 55% of alternative stocks in the same industry. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Safety
Country Japan
Industry Pharmaceuticals
Size Medium
Website mochida.co.jp
Index
Mochida Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 17-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
45 86 88 81
Growth
69 28 5 9
Safety
Safety
96 100 61 61
Sentiment
59 24 18 54
360° View
360° View
88 75 45 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
9 20 20 n/a
Opinions Change
50 50 50 50
Pro Holdings
n/a 38 26 67
Market Pulse
11 20 24 35
Sentiment
59 24 18 54
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
45 86 88 81
Growth
69 28 5 9
Safety Safety
96 100 61 61
Combined
82 92 67 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
55 83 83 82
Price vs. Earnings (P/E)
64 54 67 73
Price vs. Book (P/B)
68 89 84 84
Dividend Yield
1 74 73 57
Value
45 86 88 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
65 12 9 14
Profit Growth
67 34 27 33
Capital Growth
28 33 27 18
Stock Returns
79 68 43 47
Growth
69 28 5 9
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
86 97 100 100
Refinancing
69 91 93 93
Liquidity
92 100 82 82
Safety Safety
96 100 61 61

Similar Stocks

Discover high‑ranked alternatives to Mochida Pharmaceutical and broaden your portfolio horizons.

Shimadzu

TYO:7701
Country: Japan
Industry: Electronic Equipment
Size: X-Large
Full Stock Analysis

Cosmo Energy Holdings

TYO:5021
Country: Japan
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

KOSÉ

TYO:4922
Country: Japan
Industry: Personal Products
Size: Large
Full Stock Analysis

Nippon Shokubai

TYO:4114
Country: Japan
Industry: Specialty Chemicals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews